5 Dec 2025
Professor Patrick Tang led the project "EDC‑T: an AI‑driven promising immunotherapy for solid cancers", which was awarded a Gold Medal at the 5th Asia Exhibition of Innovations and Inventions Hong Kong, contributing to CUHK’s total of ten awards and underscoring the university’s strength in translating multidisciplinary research into impactful healthcare innovations.
8 Nov 2025
CELLmeric Limited has been awarded at the 2025 National Disruptive Technology Innovation Competition and was selected as one of six winning projects to sign an agreement with the Jing‑Jin‑Ji National Technology Innovation Center Disruptive Investment Fund. The agreement will provide follow‑on capital support and accelerate technology transfer, facilitating the advancement of the company’s R&D outcomes toward industrialization and enabling participation in the competition’s results‑matching and capital‑matching events held in Huangpu, Guangzhou.
23 Sep 2025
The 2025 Shanghai Hong Kong Innovation Project Award organized by the Shanghai Hong Kong Chamber of Commerce was held in Shanghai and concluded successfully. CELLmeric Limited’s finalist project, "A novel high‑efficiency non‑viral system for CAR‑T cell engineering," won the Best Innovation Award in the Biomedical startup track.
20 Sep 2025
CELLmeric Limited has been awarded First Runner-up at the 9th CUHK Entrepreneurship Competition. The competition was a highlight of CUHK Entrepreneur Day 2025, which brought together nearly 50 innovative alumni ventures. The accolade recognizes our significant contributions to biomedical innovation and the potential to transform cancer treatment through safer, more accessible cell therapies.
11 Jun 2025
CELLmeric Limited participated in the Hong Kong Trade Development Council’s start‑up nurturing program “Start‑up Express 2025” and was successfully selected as one of the ten outstanding start‑ups. Through the program, we gained valuable industry guidance, opportunities to connect with investors and partners, as well as media exposure, effectively helping us refine our business strategy, expand our commercial network, and accelerate the clinical translation and commercialization of its technology.
12 Apr 2025
Professor Patrick Tang and his team have been awarded the Silver Medal at the International Exhibition of Inventions of Geneva 2025 with the project "EDC-T: An AI-driven immunotherapy for solid cancers"
14 Dec 2024
PhD students supervised by Professor Patrick Tang are awarded the Gold Prize of China International College Students’ Innovation Competition 2024
5 Dec 2024
Professor Patrick Tang has been awarded the Silver Medal of Hong Kong Invention 2024 with the project "A Highly Efficient Gene Knock-in System for CAR-T Cell Engineering"
29 Jan 2024
Professor Patrick Tang and his team has made a significant breakthrough in lung cancer research by identifying the blood formation regulator Runx1 as a key driver in shaping the tumour microenvironment through macrophage‑myofibroblast transition (MMT). They demonstrated that inhibiting Runx1 can effectively suppress tumour growth without impairing normal blood formation, thereby revealing a safe and clinically relevant therapeutic target.
12 Jun 2023
Professor Patrick Tang and his team achieved a major breakthrough in lung cancer research by uncovering the role of neutrophils in tumour immune suppression. They identified Smad3 as the key regulator that drives neutrophils into a pro‑tumour state, and demonstrated that genetic or drug inhibition of Smad3 can restore their anti‑cancer activity, effectively suppressing lung cancer growth in experimental models.
10 Oct 2022
Professor Patrick Tang and his team discovered a novel mechanism—macrophage‑to‑neuron‑like cell transition (MNT)—by which macrophages in the tumour microenvironment convert into pain sensory neurons, driving cancer‑associated pain. They identified the transcription factor Smad3 as the key regulator of MNT and showed that genetic or pharmacological inhibition of Smad3 reduces tumour‑associated neurons and alleviates pain in animal models, positioning MNT as a precise and clinically relevant therapeutic target for treating primary cancer pain.
13 Jan 2022
Professor Patrick Tang and his team used single‑cell RNA sequencing to uncover a novel mechanism—macrophage‑myofibroblast transition (MMT)—that drives tumour formation in lung carcinoma. They identified Smad3 as the key transcriptional regulator initiating MMT, and showed that genetic or pharmacological inhibition of macrophage Smad3 blocks MMT and induces tumour regression in preclinical models, marking the first study to define MMT as a pathogenic process in cancer and pointing to a precise therapeutic target for treating lung cancer.
4 Dec 2021
Professor Patrick Tang has received the Youth DreamMakers Award in 2021 in recognition of his innovative non-viral gene therapy technology, which awakens anti‑cancer immunity and bring new therapeutic hope to cancer patients
23 Mar 2021